Trump’s phased generic drug tariffs could disrupt Indian drug exports and raise prescription costs across the United States. #generics #US #Trump Read more »
A UK-India pharma corridor can connect British drug discovery with Indian production, but regulatory approval and reliable supply remain decisive. #UK #pharma Read more »
India’s bulk drugs push must go beyond PLI to rebuild API capability, research links and supply-chain resilience. #API #pharma Read more »
New US tariff plans on drug imports could shake the $13 billion Indian pharma exports to their core, jeopardising generics access and investor confidence alike. #Pharma #US #tradewar Read more »
India is witnessing a dramatic rise in diabetic cases, raising questions about the role of pharmaceutical companies in deciding diabetes thresholds. #diabetes #pharma Read more »
The government may water down NMC regulations for professionals in the face of opposition from medical community. #medical #news #NMC #pharmaceuticals Read more »
The Indian pharma industry is expected to grow from $50 billion this year to $130 billion by 2030 and $450 billion by 2047. Read more »